Scottyskis2
Active member
- Joined
- Dec 17, 2022
- Messages
- 433
- Points
- 28
H
The trial, conducted by biotech company uniQure, is the first for a one-time gene therapy for Huntington’s disease. This is one of the diseases where we absolutely understand the cause, said [Ricardo Dolmetsch](https://www.uniqure.com/pioneers-leaders/leadership/dolmetsch-ricardo), president and chief scientific officer of uniQure. We thought that this is a place where there was a nice mix between what our technology can do and the really giant unmet medical need.”
The trial, conducted by biotech company uniQure, is the first for a one-time gene therapy for Huntington’s disease. This is one of the diseases where we absolutely understand the cause, said [Ricardo Dolmetsch](https://www.uniqure.com/pioneers-leaders/leadership/dolmetsch-ricardo), president and chief scientific officer of uniQure. We thought that this is a place where there was a nice mix between what our technology can do and the really giant unmet medical need.”
A gene therapy hope for halting Huntington’s disease
A one-time gene therapy aims to stop Huntington's disease at its source. But first, it has to survive clinical trials.
www.drugdiscoverynews.com